Abstract
Breast cancer is the most common cancer in women worldwide. In this study, we evaluate the potential risk factors for lymph node metastasis in invasive breast cancer patients with axillary dissection. 147 patients were included into this prospective study. The prognostic biomarkers including Ki-67, human epidermal growth factor receptor 2 (HER-2), hormone receptor status, p53, and lymph node involvement were determined by immunohistochemistry. The association between lymph node metastasis and these biomarkers was analyzed. Lymph node metastasis was found in 62 patients out of 147 patients. The high levels of Ki-67 positive (greater than 20 %) were positively correlated with a higher incidence of lymph node metastasis, including the numbers of lymph nodes that contain tumor cells and the lymph node metastatic rate. The high rate of positive lymphovascular invasion (LVI) is associated with lymph node metastasis. However, the levels of Ki-67 positive were not correlated with the positive rate of LVI. There was also no association between lymph node metastasis and other prognostic biomarkers, such as HER-2, estrogen receptor, progesterone receptor, and p53. In addition, apart from p53, the levels of Ki-67 positive were correlated with other prognostic biomarkers. Our data suggest that Ki-67 positivity has value as a prognostic and predictive biomarker in breast cancer and may be a valuable proliferation marker in routine diagnosis of breast cancer.
Similar content being viewed by others
References
Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893–2917.
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007). Overview of resistance to systemic therapy in patients with breast cancer. Advances in Experimental Medicine and Biology, 608, 1–22.
Donegan, W. L. (1997). Tumor-related prognostic factors for breast cancer. CA: A Cancer Journal for Clinicians, 47, 28–51.
Fisher, E. R., Kotwal, N., Hermann, C., & Fisher, B. (1983). Types of tumor lymphoid response and sinus histiocytosis. Relationship to five-year, disease-free survival in patients with breast cancer. Archives of Pathology and Laboratory Medicine, 107, 222–227.
Bruno, S., & Darzynkiewicz, Z. (1992). Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Proliferation, 25, 31–40.
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology, 20, 4292–4302.
Lipponen, P. (1999). Apoptosis in breast cancer: Relationship with other pathological parameters. Endocrine-Related Cancer, 6, 13–16.
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2009). Thresholds for therapies: Highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology, 20, 1319–1329.
Clarke, R. B., Howell, A., Potten, C. S., & Anderson, E. (1997). Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research, 57, 4987–4991.
Harper-Wynne, C., Ross, G., Sacks, N., Salter, J., Nasiri, N., Iqbal, J., et al. (2002). Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiology, Biomarkers and Prevention, 11, 614–621.
Paik, S. (2006). Molecular profiling of breast cancer. Current Opinion in Obstetrics and Gynecology, 18, 59–63.
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine, 351, 2817–2826.
de Azambuja, E., Cardoso, F., de Castro, G., Jr., Colozza, M., Mano, M. S., Durbecq, V., et al. (2007). Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. British Journal of Cancer, 96, 1504–1513.
Stuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008). Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast, 17, 323–334.
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25, 5287–5312.
de Boer, M., van Deurzen, C. H., van Dijck, J. A., Borm, G. F., van Diest, P. J., Adang, E. M., et al. (2009). Micrometastases or isolated tumor cells and the outcome of breast cancer. New England Journal of Medicine, 361, 653–663.
Cheang, M. C., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., et al. (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute, 101, 736–750.
Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Annals of Oncology, 16, 1723–1739.
Endl, E., & Gerdes, J. (2000). Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. Journal of Cellular Physiology, 182, 371–380.
Chae, B. J., Bae, J. S., Lee, A., Park, W. C., Seo, Y. J., Song, B. J., et al. (2009). p53 as a specific prognostic factor in triple-negative breast cancer. Japanese Journal of Clinical Oncology, 39, 217–224.
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010). Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncology, 11, 174–183.
Bozzetti, C., Musolino, A., Camisa, R., Bisagni, G., Flora, M., Bassano, C., et al. (2006). Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity. American Journal of Clinical Oncology, 29, 171–177.
Colleoni, M., Viale, G., Zahrieh, D., Bottiglieri, L., Gelber, R. D., Veronesi, P., et al. (2008). Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. Annals of Oncology, 19, 465–472.
Estevez, L. G., Cuevas, J. M., Anton, A., Florian, J., Lopez-Vega, J. M., Velasco, A., et al. (2003). Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Clinical Cancer Research, 9, 686–692.
Faneyte, I. F., Kristel, P. M., & van de Vijver, M. J. (2004). Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Research, 24, 2931–2939.
Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J. F., Borel, C., et al. (2004). Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. European Journal of Cancer, 40, 205–211.
Thames, H. D., Buchholz, T. A., & Smith, C. D. (1999). Frequency of first metastatic events in breast cancer: Implications for sequencing of systemic and local–regional treatment. Journal of Clinical Oncology, 17, 2649–2658.
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005). Proliferation marker Ki-67 in early breast cancer. Journal of Clinical Oncology, 23, 7212–7220.
Marrelli, D., Pinto, E., Neri, A., Megha, T., Gioffre, W., Cioppa, T., et al. (2006). Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: A prospective study on 675 patients. Oncology Reports, 15, 425–429.
Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., & Hortobagyi, G. N. (2006). Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): A review of the literature. Journal of Clinical Oncology, 24, 2113–2122.
Colleoni, M., Rotmensz, N., Maisonneuve, P., Sonzogni, A., Pruneri, G., Casadio, C., et al. (2007). Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Annals of Oncology, 18, 1632–1640.
Mohammed, R. A., Martin, S. G., Mahmmod, A. M., Macmillan, R. D., Green, A. R., Paish, E. C., et al. (2011). Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: Findings from a large case series with long-term follow-up. Journal of Pathology, 223, 358–365.
Ejlertsen, B., Jensen, M. B., Nielsen, K. V., Balslev, E., Rasmussen, B. B., Willemoe, G. L., et al. (2010). HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. Journal of Clinical Oncology, 28, 984–990.
Rakovitch, E., Nofech-Mozes, S., Hanna, W., Narod, S., Thiruchelvam, D., Saskin, R., et al. (2012). HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. British Journal of Cancer, 106, 1160–1165.
Nishimura, R., Okumura, Y., & Arima, N. (2008). Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: Time to progression and survival. Breast Cancer, 15, 57–64.
Pohl, G., Rudas, M., Taucher, S., Stranzl, T., Steger, G. G., Jakesz, R., et al. (2003). Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Research and Treatment, 78, 97–103.
Gasparini, G., Pozza, F., Meli, S., Reitano, M., Santini, G., & Bevilacqua, P. (1991). Breast cancer cell kinetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Research, 11, 2015–2021.
Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., et al. (1993). Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer, 29A, 1018–1023.
Bottini, A., Berruti, A., Bersiga, A., Brizzi, M. P., Bruzzi, P., Aguggini, S., et al. (2001). Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. British Journal of Cancer, 85, 1106–1112.
Moriki, T., Takahashi, T., Kataoka, H., Hiroi, M., Yamane, T., & Hara, H. (1996). Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathology International, 46, 953–961.
Kai, K., Nishimura, R., Arima, N., Miyayama, H., & Iwase, H. (2006). p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: A cohort study. International Journal of Clinical Oncology, 11, 426–433.
Yamashita, H., Toyama, T., Nishio, M., Ando, Y., Hamaguchi, M., Zhang, Z., et al. (2006). p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Research, 8, R48.
Conflict of interest
None of the authors have a conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yongxian Yin and Ke Zeng equally contribute to this work.
Rights and permissions
About this article
Cite this article
Yin, Y., Zeng, K., Wu, M. et al. The Levels of Ki-67 Positive are Positively Associated with Lymph Node Metastasis in Invasive Ductal Breast Cancer. Cell Biochem Biophys 70, 1145–1151 (2014). https://doi.org/10.1007/s12013-014-0034-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-014-0034-1